• news.cision.com/
  • Attana/
  • New study with Medical University of Innsbruck validates Attana Virus Analytics (AVA™) for SARS-CoV-2 diagnostics

New study with Medical University of Innsbruck validates Attana Virus Analytics (AVA™) for SARS-CoV-2 diagnostics

Report this content

In a new study conducted by Attana and Medical University of Innsbruck, a number of individuals have been tested for COVID-19 with both AVATM and EUROIMMUN’s ELISA-based technology. The results show that Attana’s technology accurately measures the concentration of SARS-CoV-2 antibodies with at least the precision of current FDA-approved technology.

Description of results

The Medical University of Innsbruck delivered samples from 6 different individuals in Austria, on which Attana performed analyses using the AVA platform. All samples have also undergone tests for SARS-CoV-2 spike-specific IgG antibodies using EUROIMMUN’s ELISA-based technology in a separate lab in Innsbruck.

The graph below displays the AVA results for the 6 samples along with an FBS control sample. All samples show different levels of general immune system response (step 2), specific antibody response (step 3) and SARS-CoV-2 IgG antibody response (step 4). The FDA-approved ELISA technology validates the AVA analyses since the SARS-CoV-2 IgG antibody response (step 4) is significantly higher in the two samples which are confirmed positive in the ELISA-test.

AVA results from study with the Medical University of Innsbruck

Implications of results

The comparison with the ELISA-results indicate that Attana’s technology can measure the concentration of SARS-CoV-2 antibodies with at least the same precision as current FDA-approved technology. Furthermore, AVA’s analyses show more nuanced results. For example, the two ELISA-positive individuals have distinctly different immunity profiles when comparing their AVA curves. Attana will, in continued collaboration with the Medical University of Innsbruck among others, further develop AVA’s analyses to improve the understanding of immunity towards COVID-19.

Comment from Teodor Aastrup, CEO of Attana:

”This study further confirms that AVA is capable of quantifying the concentration of SARS-CoV-2 antibodies from patient serum samples, at least as well as today’s FDA-approved tools. And although the quantitative measure of antibody concentration is an important part of an individual’s potential immunity, it does not give a complete picture. The aim of the AVA platform is to deliver a “degree of immunity” based upon both quantitative and qualitative parameters from patient samples.”

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com





Documents & Links